HNP1-3, Human, Natural
Human neutrophil alpha-defensins (Human Neutrophil Peptides, HNP) belong to the family of cationic
trisulfide-containing microbicidal peptides. Three highly homologous human defensins stored in
azurophilic granules of polymorphonuclear leukocytes (PMN), HNP 1-3, account for about 5% of total
PMN protein and comprise about 99% of the total defensin content of the neutrophils with traces of
HNP-4.
HNP-1, HNP-2 and HNP-3 are encoded by two genes DEFA1 and DEFA3 localized to chromosome 8.
Number of gene copies substantially varies between individuals with complete lack of the DEFA3 allele
in 10% subjects. DEFA1 and DEFA3 encode identical peptides except the conversion of the first amino
acid from alanine in HNP-1 to aspartic acid in HNP-3; HNP-2 represent N-terminally truncated iso-form
lacking the first amino acid.
HNP 1-3 are capable to kill and/or inactivate a broad spectrum of bacteria, fungi or some enveloped
viruses and have recently been shown to exert the anti-HIV activity produced by CD8+ T cells of HIVnonprogressors.
HNP 1-3 have the potential to modulate immune response and inflammation by
inducing the chemokine interleukin-8 (IL-8) in epithelial cells and modulating cytokine expression in
several cell types and causing chemotaxis to monocytes, T cells and immature dendritic cells.
Defensins are relatively resistant to proteolysis, low pH and boiling. Activation of neutrophils leads to
rapid release of HNP. HNP can be measured in plasma and other body fluids during infection and
inflammation. Micromolar concentrations of HNP are described in septic blood, while in normal plasma
very low levels of HNP are present. (HNP 1-3 can be measured using Human Neutrophil Defensin 1-3
(HNP 1-3) ELISA, Cat. # HK317).
You may also like…
You may be interested in…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- Discover Cross-Reactive Complement ELISA for NHP ResearchBridging Human and NHP Complement Research. At Hycult Biotech, we understand the importance of testing therapeutic agents on non-human primates (NHP) samples in order to get approval to enter clinical phases. That is why we have committed to the following initiative: Testing our existing complement ELISA assays for NHP research. Why Non Human Primate Samples… Read more: Discover Cross-Reactive Complement ELISA for NHP Research
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis